Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 348-353

  Hafkin, J ^a   Modongo, C ^b   Newcomb, C ^a   Lowenthal, E ^a   MacGregor, R R ^a   Steenhoff, A P ^a   Friedman, H ^a   Bisson, G P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOTSWANA UPENN PARTNERSHIP   (Botswana)

Author keywords

HIV; Sub Saharan Africa; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; STREPTOMYCIN; TERIZIDONE;

ADULT; AMBULATORY CARE; ARTICLE; BOTSWANA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SEIZURE; SPUTUM CULTURE;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BOTSWANA; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84874080762     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0100     Document Type: Article

References (31)

1. Maartens G, Wilkinson R J. Tuberculosis. Lancet 2007; 370: 2030-2043.
2. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
3. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
4. Rajbhandary S S, Marks S M, Bock N N. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1012-1016.
5. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
6. Fischl M A, Daikos G L, Uttamchandani R B, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992; 117: 184-190.
7. Busillo C P, Lessnau K D, Sanjana V, et al. Multidrug-resistant Mycobacterium tuberculosis in patients with human immuno-deficiency virus infection. Chest 1992; 102: 797-801.
8. Turett G S, Telzak E E, Torian L V, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-1244.
9. Salomon N, Perlman D C, Friedmann P, Buchstein S, Kreis-wirth B N, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1245-1252.
10. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
11. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
12. Franzetti F, Gori A, Iemoli E, et al. Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 553-560.
13. Telzak E E, Chirgwin K D, Nelson E T, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Int J Tuberc Lung Dis 1999; 3: 337-343.
14. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multidrug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
15. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
16. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
17. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS ONE 2009; 4: e7186.
18. Brust J C, Lygizos M, Chaiyachati K, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS ONE 2011; 6: e15841.
19. Joint United Nations Programme on HIV/AIDS. UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: UNAIDS, 2010.
20. World Health Organization. Global tuberculosis control. WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
21. Nelson L J, Talbot E A, Mwasekaga M J, et al. Anti-tuberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005; 366: 488-490.
22. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
23. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
24. Jeon D S, Shin D O, Park S K, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci 2011; 26: 33-41.
25. Kwon Y S, Kim Y H, Suh G Y, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
26. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009; 150: 766-775.
27. Laniado-Laborin R. Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered. Expert Rev Respir Med 2010; 4: 143-146.
28. Brust J C M, Shah N S, Scott M, Chaiyachati K, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
29. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
30. Lawn S D, Campbell L, Kaplan R, Little F, Morrow C, Wood R. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infect Dis 2011; 11: 258.
31. Evans S R, Ellis R J, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25: 919-928.